NEW YORK (GenomeWeb News) – Gen-Probe this week said that it has begun a clinical study of its Progensa PCA3 assay, a molecular test for determining the need for a repeat prostate biopsy. The firm said that the trial would be conducted to support an application to the US Food and Drug Administration for clearance of the assay.

Gen-Probe said that it expects to enroll around 500 men, all of whom have had a negative prostate biopsy, at 10 or more clinical trial sites. It expects the trial to conclude in less than a year, after which it will file the application with FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.